Ticho Barry 4

4 · Stoke Therapeutics, Inc. · Filed Mar 17, 2026

AI-generated summary of this filing

Updated Mar 17, 2026

Stoke Therapeutics CMO Ticho Barry Converts 33,850 RSUs; Shares Disposed

What Happened

Ticho Barry, Chief Medical Officer of Stoke Therapeutics (STOK), had derivative awards (RSUs) convert into 33,850 shares on March 15, 2026 (13,100 + 10,000 + 10,750). The filing shows the shares were both "acquired" by conversion and "disposed" the same date. Reported exercise/conversion price per share is $0.00 and the filing lists $0 total value for these entries.

Key Details

Transaction date: March 15, 2026; Form 4 filed March 17, 2026 (timely filing).
Reported price/value: $0.00 per share; $0 total as reported for these derivative conversions.
Shares affected: 33,850 shares converted and 33,850 shares disposed (split across three award lines).
Shares owned after transaction: Not disclosed in the provided filing excerpt.
Footnotes: F1–F4 indicate these were restricted stock units (RSUs) that convert 1 RSU = 1 share and vest in quarterly/annual tranches (1/4 of award annually beginning March 15 of 2024, 2025 and 2026 as applicable).
Transaction type/code: Reported under derivative exercise/conversion (Form 4 code M).

Context

These entries reflect RSU settlement (conversion of RSUs into shares) and immediate disposition of the resulting shares on the same date. The filing does not state the nature of the disposition (sale, transfer, or tax-withholding) or any proceeds. For retail investors: conversions of RSUs followed by same-day dispositions are common for vesting and payroll/tax-related actions and do not by themselves indicate the insider's market view.

Form 4

Period: 2026-03-15

CHIEF MEDICAL OFFICER

Transactions

Exercise/Conversion
Common Stock
2026-03-15+13,100→ 32,898 total
Exercise/Conversion
Common Stock
2026-03-15+10,000→ 42,898 total
Exercise/Conversion
Common Stock
2026-03-15+10,750→ 53,648 total
Exercise/Conversion
Restricted Stock Units
[F1][F2]
2026-03-15−13,100→ 13,100 total
Exp: 2027-03-15→ Common Stock (13,100 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F3]
2026-03-15−10,000→ 20,000 total
Exp: 2028-03-15→ Common Stock (10,000 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F4]
2026-03-15−10,750→ 32,250 total
Exp: 2029-03-15→ Common Stock (10,750 underlying)

Footnotes (4)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
[F2]The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.
[F3]The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the Issuer through each vesting date.
[F4]The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

Signature

/s/ Jonathan Allan, Attorney-in-Fact|2026-03-17

1 file